STAAR Surgical Company (STAA) News
Filter STAA News Items
STAA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
STAA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest STAA News From Around the Web
Below are the latest news stories about STAAR SURGICAL CO that investors may wish to consider to help them evaluate STAA as an investment opportunity.
ProDex (PDEX) Moves 23.0% Higher: Will This Strength Last?ProDex (PDEX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
Staar Surgical price target lowered to $39 from $49 at BTIGBTIG lowered the firm’s price target on Staar Surgical (STAA) to $39 from $49 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models on Medical Technology names reflecting management commentary, product launch momentum, competitive updates, and macroeconomic factors. For Staar, BTIG has lowered its ICL – Implantable Collamer Lens – growth expectations in FY25 and beyond amid continued macroeconomic weakness in China, assuming a similar high single digi |
STAAR Surgical to Participate in BTIG Ophthalmology DayLAKE FOREST, Calif., November 25, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors and a fireside chat at the 4th Annual BTIG Ophthalmology Day. |
Implied Volatility Surging for STAAR Surgical (STAA) Stock OptionsInvestors need to pay close attention to STAAR Surgical (STAA) stock based on the movements in the options market lately. |
STAAR Surgical to Participate in Stephens Annual Investment Conference (NASH2024)LAKE FOREST, Calif., November 13, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with STAAR Management at the upcoming Stephens Annual Investment Conference, which will be held in Nashville, TN. |
A Dive into Staar Surgical (STAA) International Revenue Trends and ForecastsEvaluate Staar Surgical's (STAA) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance. |
Staar Surgical Co (STAA) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amidst ChallengesStaar Surgical Co (STAA) reports a 10% increase in net sales and robust regional performance despite macroeconomic headwinds. |
STAAR Surgical Company Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextLast week, you might have seen that STAAR Surgical Company ( NASDAQ:STAA ) released its third-quarter result to the... |
STAAR Surgical Third Quarter 2024 Earnings: Beats ExpectationsSTAAR Surgical ( NASDAQ:STAA ) Third Quarter 2024 Results Key Financial Results Revenue: US$88.6m (up 10% from 3Q... |
CORRECTING and REPLACING STAAR Surgical Reports Third Quarter 2024 ResultsLAKE FOREST, Calif., October 31, 2024--The end of the paragraph after bullets in the "Outlook" section of release should read: APAC sales growth of 5% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%) and all other APAC countries approximately 10-20% growth (prior outlook was flat). (Instead of: APAC sales growth of 4% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%). |